💡 Welcome to Make Money, part of the Finance Frontier AI podcast series—where we decode asymmetric investment opportunities hiding in plain sight. In this episode, Max and Sophia broadcast from a biotech innovation hub outside Princeton, New Jersey, just miles from the R&D corridors that helped launch CorMedix’s lead product, DefenCath. With profitability locked in, cash on hand, and a clear path to label expansion, CorMedix ($CRMD) is no longer a pre-revenue bet—it’s a re-rating story with institutional tailwinds and a shot at 8X returns.

🔹 Profitability in Q4, Explosion in Q1 – From $0 to $43.5M in full-year 2024 sales. Q1 2025? $39M and $22.5M+ EBITDA.
🔹 The DefenCath Advantage – First FDA-approved catheter lock solution (CLS). 71% infection reduction. 10.5 years of exclusivity.
🔹 Dialysis Market Domination – Already in 60% of outpatient centers, including 4 of the top 5 U.S. dialysis chains.
🔹 TPN Trial = Hidden Upside – Phase 3 study for patients on Total Parenteral Nutrition launching now. $500–750M market potential.
🔹 The 8X Valuation Math – $25 short-term target based on 5× 2026E sales. $75 long-term with pediatric + TPN + federal expansion.
🔹 Regulatory Moat – NTAP, TDAPA, Orphan Drug, pediatric trial—all locking out competition through 2034.
🔹 Institutional Footprint – BlackRock, Vanguard, Elliott Management on the cap table. Insiders are buyers, not sellers.
🔹 Options-Friendly Setup – IV over 100%, tight float, cash-positive. ITM + OTM call layering explained in Segment 6.

🚀 This isn’t a hope trade. CRMD is already printing profits and scaling.
🚀 Biotech Volatility = Strategy Playground – Dips are entries. IV is high. Options give leverage, not just risk.
🚀 Market Mispricing Playbook – Patent fears, customer concentration headlines, and sector fatigue = opportunity window.
🚀 Reimbursement Edge = Accelerated Adoption – TDAPA and NTAP drive immediate returns for providers. And it’s locked in.
🚀 TPN + Pediatric = Optionality Stack – This isn’t just a CLS play. It’s a platform rooted in taurolidine’s unique mechanism.
🚀 Cash Cushion, No Debt – $77.5M in the bank. That’s breathing room most biotech players dream of.

✅ CRMD is already in the cashflow club. And the market hasn’t caught up.
✅ The $25 price target is backed by earnings math—not dreams.
✅ $75 isn’t hype—it’s the 5-year if TPN, pediatrics, and institutional buyers align.
✅ The asymmetric edge is live. Mispricing + momentum + margin = multi-X setup.
✅ This episode doesn’t just share a stock. It shares a system for capturing biotech rerates before Wall Street notices.

📢 Visit FinanceFrontierAI.com to explore all episodes grouped by series—Make Money, AI Frontier AI, Finance Frontier, and Mindset Frontier AI.
📲 Follow us on X for asymmetric setups, AI deep dives, and portfolio strategy drops.
🎧 Subscribe on Apple Podcasts and Spotify to stay ahead of the next 3–10X moves.
🔥 Help us grow—leave a 5-star review and share this episode with a friend. Every listen compounds your edge.